EPO and myelodysplastic syndrome: Currently, several treatment options are available for patients with MDS: hypomethylating agents (e.g., azacytidine), hematopoietic stimulating agents (e.g., erythropoietin, G-CSF, and luspatercept), supportive care (e.g., blood and platelet transfusions and antibiotics), immunomodulatory agents (e.g., lenalidomide and cyclosporine), low-dose or intensive chemotherapy, and iron overload chelation (deferasirox) [6,7].